117519-07-0Relevant articles and documents
HMOX1 inducers
-
Page/Page column 150, (2020/09/18)
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.
NITROGENATED HETEROCYCLIC COMPOUND
-
Paragraph 0651, (2015/03/28)
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
Non-nucleoside reverse transcriptase inhibitors
-
, (2008/06/13)
Provided are compounds of the general formula I: wherein R2 is selected from the group consisting of H, F, Cl, (C1-4) alkyl, (C3-4) cycloalkyl and CF3; R4 is H or Me; R5 is H, Me or Et, wit
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption
Isaacs, Richard C. A.,Cutrona, Kellie J.,Newton, Christina L.,Sanderson, Philip E. J.,Solinsky, Mark G.,Baskin, Elizabeth P.,Chen, I-Wu,Cooper, Carolyn M.,Cook, Jacquelynn J.,Gardell, Stephen J.,Lewis, S. Dale,Lucas Jr., Robert J.,Lyle, Elizabeth A.,Lynch Jr., Joseph J.,Naylor-Olsen, Adel M.,Stranieri, Maria T.,Vastag, Kari,Vacca, Joseph P.
, p. 1719 - 1724 (2007/10/03)
1 (L-374,087) is a potent, selective, efficacious, and orally bioavailable thrombin inhibitor that contains a core 3-amino-2-pyridinone moiety. Replacement of the C6 pyridinone metyl group of 1 by a propyl group gave 5 (L-375,052), which retained all the excellent properties of 1, and also yielded higher plasma levels after oral dosing in dogs and rats.
PYRIDINONE THROMBIN INHIBITORS
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: STR1 for example: STR2
Synthesis of substituted azaoxindoles for the preparation of aza-tenidap analogs
Robinson, Ralph P.,Donahue, Kathleen M.,Son, Paul S.,Wagy, Steven D.
, p. 287 - 293 (2007/10/03)
The preparation of a set of eight azaoxindoles bearing substituents on the aromatic nucleus is outlined. These compounds were required for the preparation of aza-analogs of the anti-inflammatory oxindole tenidap. Two methods of synthesis were used, the fi